CureDRPLA co-founders, Paul and Andrea Compton, have a son with DRPLA and their personal experiences with this devastating condition are the driving force behind CureDRPLA. Earlier this year, CureDRPLA announced that n-Lorem had an experimental treatment for DRPLA and...
Nissan Chemical and Sanwa Kagaku announce plans to develop drug for DRPLA
Nissan Chemical Corporation and Sanwa Kagaku Kenkyusho Co., Ltd., two Japanese companies, have announced they recently co-created an antisense oligonucleotide (ASO) for DRPLA. ASOs have emerged as a promising strategy for various neurodegenerative conditions,...
Group of volunteers organize booth at neurology conference in Tokyo
Junko Shiozawa, Advisory Board Member to CureDRPLA, has created a community of Japanese families affected by DRPLA. They offer peer support to each other and host online meetings. Since DRPLA is more common in Japan, it was important for us to create a Japanese...
Interviews with patients and caregivers to understand DRPLA symptoms and impacts on daily life
CureDRPLA has been funding research that aims to better understand DRPLA symptoms and how this condition develops over time, such as the DRPLA Natural History and Biomarkers Study. While such research projects are essential for advancing research towards clinical...
Announcing DRPLA n-of-1 clinical trial
This announcement was initially published on our website on February 12, 2024. You can find a pdf version of the announcement here. Dear DRPLA community, Since we established CureDRPLA in 2019, our mission has been to connect families, physicians and scientific...